Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    FDA approves combo immunotherapy for mesothelioma, atezolizumab strikes out in ovarian cancer, and more

    FDA approves combo immunotherapy for mesothelioma, atezolizumab strikes out in ovarian cancer, and more

    FromBlood & Cancer

    Start listeningView podcast show

    FDA approves combo immunotherapy for mesothelioma, atezolizumab strikes out in ovarian cancer, and more

    FromBlood & Cancer

    ratings:
    Length:
    12 minutes
    Released:
    Oct 13, 2020
    Format:
    Podcast episode

    Description

    Hematology-Oncology News:  Radiotherapy planning scans reveal breast cancer patients’ CVD risk (https://bit.ly/2FeoJiH) FDA OKs combination immunotherapy for first-line mesothelioma treatment (https://bit.ly/2Ff77mS) Apatinib plus gefitinib: Better PFS but more toxicity (https://bit.ly/34IyVsn) Atezolizumab strikes out in ovarian cancer (https://bit.ly/3iPjXG1) Email Blood & Cancer at podcasts@mdedge.com and learn more at https://www.mdedge.com/podcasts/blood-cancer        
    Released:
    Oct 13, 2020
    Format:
    Podcast episode

    Titles in the series (100)

    The official podcast feed of MDedge Hematology-Oncology, part of the Medscape Professional Network. On Thursdays, Dr. David Henry interviews key opinion leaders and rising stars in hematology and oncology. The information in this podcast is provided for informational and educational purposes only.